Oramed: Rises on JV to develop oral COVID-19 vaccines

Oramed Pharmaceuticals

19/03/2021 14:26

** Shares in pharmaceuticals co  ORMP.O  rise 2.6% to $9.56 
    ** ORMP to form a joint venture focused on the development
of novel oral COVID-19 vaccines  urn:newsml:reuters.com:*:nPreLCY7Ja
    ** The new company, Oravax Medical Inc, is based on Oramed's
proprietary oral delivery technology and Premas Biotech Pvt
Ltd's novel vaccine technology
    ** The oral delivery of the vaccine should allow for
widescale inoculation and easier distribution of the vaccine
without requiring an injection - Oramed
    ** Oravax anticipates commencing a clinical study during Q2 
of 2021
    ** Shares have more than doubled in value this year 

 (Reporting by Arundhati Sarkar in Bengaluru)
 ((Arundhati.Sarkar@thomsonreuters.com;
twitter.com/Arundhati_05; +1 646 223 8780 Ext: 2776))